Immune checkpoint inhibitors (ICI) may overcome cancer cells' ability to evade the immune system and proliferate. The long-term benefit of ICI in the metastatic setting led to evaluate neoadjuvant ICI approaches in several tumor types such as melanoma, non-small cell lung cancer, and breast and bladder cancer. We summarize the current evidence for the efficacy of neoadjuvant ICI in cancer and discuss several unresolved challenges, including the role of adjuvant treatment after neoadjuvant ICI, the efficacy in oncogenic addicted tumors, and standardizing pathological assessment.
Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 May 20 [Epub ahead of print]
Jose Carlos Benitez, Jordi Remon, Benjamin Besse
Medical Oncology, Institut Gustave Roussy., Cancer Medicine Department, Delfos Hospital., Medical Oncology, Institut Gustave Roussy .